
Palette Life Sciences
Palette Life Sciences, a medical device company, treated urological, urogynecological, colorectal, radiotherapy, and oncology conditions with non-animal stabilized hyaluronic acid.
- Acquired by Teleflex
- Stockholm, SESweden
Palette Life Sciences was a medical device company treating urological, urogynecological, colorectal, radiotherapy, and oncology conditions, and its portfolio included Barrigel, Deflux, and Solesta. Barrigel was a NASHA spacer designed to reduce radiation delivered to the rectum during prostate cancer radiation therapy, while Deflux and Solesta were NASHA-based tissue bulking agents for pediatric vesicoureteral reflux and fecal incontinence.
Its products were the first or only FDA-cleared or FDA-approved treatment of their kind. Barrigel was the first and only FDA-cleared hyaluronic acid rectal spacer, and Deflux was the only FDA-approved injectable treatment for vesicoureteral reflux.
Similar Companies

Hyperice

Delfi Diagnostics

Shoreline Biosciences

Myriad Genetics

Morepen Laboratories

Direct Biologics

Strand Therapeutics

Setpoint Medical

Galvanize Therapeutics

Expedition Therapeutics

The Beauty Tech Group

Medistim

Barco

Nanosonics

Lumibird

Orthopediatrics

SD BIOSENSOR

MiMedx Group

UltraGreen.ai

SmartCella

Medrobotics

Ring Therapeutics
Quick Facts
Who are Palette Life Sciences' competitors?
Companies similar to Palette Life Sciences include Hyperice, Delfi Diagnostics, Shoreline Biosciences and Myriad Genetics.
When was Palette Life Sciences founded?
Palette Life Sciences was founded in 2018.
Where is Palette Life Sciences' headquarters located?
Palette Life Sciences' headquarters is located in Stockholm, SE.
How much disclosed funding has Palette Life Sciences raised?
As of Jul 26, 2023, Palette Life Sciences has disclosed funding of $30M (USD). Undisclosed round amounts are excluded.
Classification
- Industry
- Technology
- Geographic Exposure
- Model
- Revenue
- Customer
- Headquarters
- Fogdevreten 2A
- Stockholm, 17165
- SE